Summary:
Cyrex Laboratories has launched BiomeBurden, a comprehensive 3-panel blood test that evaluates immune responses to microbial, yeast, and mold triggers, offering deeper insights into gut-related immune imbalances and their role in chronic conditions.

Takeaways:

  1. Immune-Centric Testing: Unlike traditional gut tests, BiomeBurden focuses on immune activation—measuring antibodies, T cells, and lymphocytes—to identify how the body reacts to microbial antigens.
  2. Holistic Gut Analysis: The three-panel system screens for Candida species, pathogenic bacteria, mold, and cross-reactive tissue antigens, with advanced panels assessing Th1/Th2/Th17 immune responses.
  3. Functional Medicine Breakthrough: Developed over 20 years by functional immunology pioneer Dr. Aristo Vojdani, the test empowers personalized care by identifying root causes of autoimmune and inflammatory symptoms.

Cyrex Laboratories, a clinical laboratory specializing in functional immunology and autoimmunity, has announced the launch of BiomeBurden, its newest entry in gut biome testing. This advanced 3-panel testing approach is designed to uncover multiple immune responses to microbes, yeast, and mold, including antibodies, lymphocytes, and T cells.

The foundational MycoBiomeBurden panel screens for 6 key Candida species, multiple Candida Albican virulence factors such as germ tube and candidalysin, and several food-derived molds. The second panel MicroBiomeBurden expands detection to several cross-reactive tissue antigens, 3 species of aerobic bacteria, and 4 species of anaerobic bacteria. The third panel, BiomeBurden Complete, includes the first two panels plus several flow cytometry tests for T-cell function and lymphocyte activity of Th1, Th2, and Th17—all critical indicators of potential immune response to the tested antigens.

BiomeBurden Identifies Imbalances in Gut Health

In recent years, both patients and healthcare providers have become increasingly aware of the important role that the gut microbiome plays in supporting immune health and balance. When this delicate balance is disrupted—especially by an overgrowth of certain fungal species—it can trigger chronic inflammation and impact overall well-being. Candida species, while naturally present in the body, can become problematic in certain individuals when they grow out of balance. This overgrowth has been linked to ulcerative colitis, liver autoimmunity, Rett syndrome, and other autoimmune conditions. By identifying these imbalances early, there is an opportunity to better understand the root causes of chronic symptoms and take proactive steps toward improved long-term health.

“This launch marks a key milestone for our company as we continue to transform how people understand and manage their health,” says Mark McDonough, CEO of Cyrex Laboratories. “With BiomeBurden™, Cyrex is redefining microbial testing by focusing on immune activation—not just presence of antigens—to reveal how the body is actively responding. We have designed these panels to empower healthcare practitioners to uncover hidden microbial triggers through an expanded screening of potential immune responses that may drive chronic conditions. It’s a more personalized, preventive approach—one focused on identifying root causes, not just managing symptoms.”

Test is Result of 20 Years of Research

BiomeBurden is the result of over 20 years of research and development by Aristo Vojdani PhD, considered the father of Functional Medicine and a pioneer in this field with over 20 patents and numerous industry-changing innovations.

“Unlike traditional stool or swab tests that focus primarily on the gut, the BiomeBurden blood test offers a more comprehensive view of the body’s immune response to fungal and microbial triggers,” says Vojdani, chief scientific advisor of Cyrex. “By analyzing immune markers in the blood, we can assess not only the presence of specific organisms but also how the immune system is reacting across multiple systems—not just the gut. This provides clinicians with a better understanding of how the mycobiome and microbiome contribute to autoimmunity, as well as a deeper, more holistic understanding of a patient’s overall immune health.” 

All Cyrex Arrays are available to consumers exclusively through an order from a physician or other licensed healthcare professional.

Featured Image: BiomeBurden is an advanced 3-panel test designed to uncover multiple immune responses to microbes, yeast, and mold, including antibodies, lymphocytes, and T cells. Image: Cyrex Laboratories